Recent News

• 10.03.2025 - Astria Therapeutics to Present at Upcoming 2025 HAEi Regional Conference EMEA
• 10.02.2025 - Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 10.02.2025 - Astria Therapeutics Now Enrolling HAE Patients in the European Union for the Phase 3 ALPHA-ORBIT Trial
• 09.17.2025 - Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology
• 09.04.2025 - Cantor Global Healthcare Conference
• 09.03.2025 - Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 09.03.2025 - Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025
• 08.27.2025 - Astria Therapeutics to Present at Upcoming Cantor Global Healthcare Conference
• 08.12.2025 - Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
• 08.06.2025 - Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan

Recent Filings

• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.12.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 08.06.2025 - EX-99.1 EX-99.1
• 08.06.2025 - 8-K Current report
• 06.18.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors